iTOL-401

iTOL-401 is a nanoparticle formulation being developed for use in large organ transplants to induce local immune tolerance and eliminate the need for life-long immunosuppression. It is part of a platform technology from iTolerance, Inc., which leverages immunomodulatory approaches—specifically, synthetic protein-based nanoparticles—to enable transplantation of tissues or organs without chronic systemic immunosuppression. The mechanism is based on localized immune modulation at the transplant site, likely utilizing similar principles as other products in the iTolerance pipeline (such as SA-FasL microgel), though specific molecular details for iTOL-401 are not fully disclosed. The primary indication under development is prevention of graft rejection in large organ transplantation[1][2][5][7].